A Single Blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Repeat Doses of GSK2330672 in Healthy Volunteers, Given Alone and With a Single Day of Dosing With GSK1614235
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs GSK 2330672 (Primary) ; GSK 1614235
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned End Date changed from 1 Oct 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 09 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.